
Former K-9 busy as a bee sniffing out threats to Michigan State University colonies
The Pollinator Performance Center's wide range of projects includes developing a training program for dogs to use their sensitive noses to uncover a bacterial disease called American foulbrood that threatens honey bee larvae.
Bees and other pollinators have been declining for years because of disease, insecticides, climate change and lack of a diverse food supply. A considerable portion of the human diet comes from plants pollinated by bees.
Maple, who once served as a human remains detection dog for the St. Joseph County sheriff's office, has created quite the buzz.
The panting 9-year-old English springer spaniel stood patiently on a recent weekday as Sue Stejskal, her longtime owner, trainer and handler, slowly placed the retired K-9 in a yellow protective suit. The garment includes a veil for her head and four booties worn on her paws in case Maple steps on a bee.
"Much like with humans, we recognize that if a dog is going to be in an active bee yard, they need to wear the same personal protective equipment as people do," said Stejskal, a Michigan State graduate who has been training dogs over a quarter-century for law enforcement and other uses. "You can't buy them on Amazon for dogs. So, there's been some altering and testing."
Maple suffered an injury while on a case in Ontario, forcing her to retire as a detection K-9 in 2024. But fate intervened.
Meghan Milbrath, an MSU professor whose lab studies risk factors that affect honey bees' health, was working to establish diagnostic and screening tools for honey bee diseases. A veterinarian who participated in a training about honey bees put Milbrath in touch with Stejskal.
They met, and the dog detection plan was born.
Stejskal then set about teaching an old dog a new trick. New to Maple, anyway. Maryland's agriculture department has also used canine detection methods in beehives.
Michigan State's objective is to train many more dogs to join the ranks. Milbrath said she is documenting Maple's training and plans to write a book with Stejskal to educate other teams about their strategy.
Maple, clad in her yellow suit, raced between hive boxes during a recent demonstration. When she found the scent clue left for her, Maple stopped at the box and coolly looked up at Stejskal.
"Good girl. Yes," Stejskal enthusiastically said, before removing Maple's veil and tossing a green, Michigan State-branded toy her way.
Stejskal recognizes the work they're doing is important.
"It's a cool project," Stejskal said. "But I was over-the-moon excited, because my dog would still have joy in her life and would still be able to work."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fox News
6 minutes ago
- Fox News
Doctor reveals why he is 'concerned' about mental health screenings in Illinois schools
Dr. Leonard Sax, author of 'The Collapse of Parenting,' joins 'Fox & Friends' to discuss why he is concerned about a new law requiring schools in Illinois to screen kids' mental health.
Yahoo
34 minutes ago
- Yahoo
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
The celebration marks a major milestone for the patent-pending, next-generation, rapid, compact, and hand-held Daxor BVA™. Oak Ridge, TN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces that the official replay of its Nasdaq Closing Bell Ceremony is now available. The ceremony, which took place on August 8, 2025, commemorated the FDA 510(k) clearance for its patent-pending, next-generation, rapid, compact, hand-held, lab-based new Daxor BVA™ (Blood Volume Analyzer). You can watch the full replay of the event here: Closing Ceremony. For more information, visit Sign up to receive news on Daxor's innovative technology HERE. About Daxor Corporation Daxor Corporation (NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor's patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion. Forward-Looking Statements Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:Investor Relations Contact:Bret ShapiroCOO – Head of Capital MarketsCOREIR(561)-479-8566-Cellbrets@ in to access your portfolio
Yahoo
34 minutes ago
- Yahoo
Here's Why Halozyme Therapeutics (HALO) Traded Town in Q2
Meridian Funds, managed by ArrowMark Partners, released its 'Meridian Growth Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets made a significant rebound during the quarter, increasing 23% from intra-period lows to close at record highs. Against this backdrop, the fund returned 4.10% (net) compared to the Russell 2500 Growth Index's 11.31% return. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Meridian Growth Fund highlighted stocks such as Halozyme Therapeutics, Inc. (NASDAQ:HALO). Based in San Diego, California, Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company. The one-month return of Halozyme Therapeutics, Inc. (NASDAQ:HALO) was 11.11%, and its shares gained 12.32% of their value over the last 52 weeks. On August 11, 2025, Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock closed at $62.89 per share, with a market capitalization of $7.356 billion. Meridian Growth Fund stated the following regarding Halozyme Therapeutics, Inc. (NASDAQ:HALO) in its second quarter 2025 investor letter: "Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme enables the subcutaneous delivery of biologics and fluids, transforming hours-long intravenous (IV) infusions into quick injections that can be delivered in just minutes. By doing so, ENHANZE can significantly reduce the treatment burden for patients and ease capacity constraints for healthcare providers. Shares of Halozyme declined during the period following news that the Centers for Medicare & Medicaid Services (CMS) may reconsider how it classifies reformulated drugs using ENHANZE. Under the proposed change, such formulations may no longer qualify as 'new drugs,' potentially subjecting them to Medicare price negotiations earlier than previously expected. While the proposal remains under review, we believe ENHANZE continues to offer meaningful advantages—including fewer injection-site reactions and substantial time and cost savings for clinics—making it an important innovation in drug delivery. We slightly reduced our position in the company during the quarter." An image of a research technician wearing lab coat with a syringe full of biopharmaceuticals. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 31 hedge fund portfolios held Halozyme Therapeutics, Inc. (NASDAQ:HALO) at the end of the first quarter, which was 25 in the previous quarter. In the second quarter of 2025, Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported revenue of $326 million, representing 41% year-over-year increase. While we acknowledge the potential of Halozyme Therapeutics, Inc. (NASDAQ:HALO) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Halozyme Therapeutics, Inc. (NASDAQ:HALO) and shared the list of most undervalued biotech stocks to buy. Halozyme Therapeutics, Inc. (NASDAQ:HALO) rose in the previous quarter due to strong earnings and its decision to focus on its core business. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data